BioMarin Pharmaceutical | BMRN - Cost Of Sales


BioMarin Pharmaceutical reported $199.48M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Bayer EUR 5.23B 731M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Insmed USD 49.5M 3.34M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Moderna USD 955M 503M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.76B 344M Dec/2025
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
United Therapeutics USD 133.4M 341.3M Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026